查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095222

生物製劑契約製造市場：全球預測，2026-2032年

Biologics Contract Manufacturing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物製劑契約製造市場將成長至 458.6 億美元，複合年成長率為 8.35%。

主要市場統計數據
基準年 2025 261.5億美元
預計年份：2026年 282.6億美元
預測年份 2032 458.6億美元
複合年成長率 (%) 8.35%

生物製劑契約製造執行摘要

生物製劑契約製造已成為生物製藥開發公司尋求擴充性、合規且經濟高效的單株抗體、重組蛋白、疫苗、細胞和基因療法、生物相似藥以及下一代生物製藥生產的戰略支柱。這項需求源自於複雜的分子研發管線、生物製藥獲批數量的不斷成長、生物相似藥的日益普及，以及對哺乳動物細胞培養、微生物發酵、病毒載體生產、灌裝和包裝、分析測試和監管文件編制等專業能力的需求。與傳統小分子藥物的生產不同，生物製藥生產需要對生物系統進行嚴格控制，確保低溫運輸完整性，防止污染，進行製程表徵，並採用品質源自於設計 (QbD) 框架。因此，申辦方越來越依賴合約開發和生產組織 (CDMO) 來加速臨床和商業化準備，同時確保符合現行藥品生產品質管理規範 (GMP) 標準。此外，該行業還受到許多因素的影響，例如優先考慮供應鏈韌性、本地化政策、技術轉移要求，以及加強對資料完整性、批次可追溯性和生物製藥安全性的監控。對於產業相關人員，競爭優勢在於靈活的生產能力、先進的生物製程專業知識、健全的品質體系，以及滿足從細胞株開發和製程最佳化到商業化生產和上市後變更管理等整個生命週期需求的能力。

正在重塑生物製劑生產外包格局的變革性變化。

隨著開發商從單一產品外包轉向整合式長期生產夥伴關係，生物製劑契約製造產業正經歷一場結構性變革。一次性生物反應器、模組化無塵室基礎設施、封閉式製程、連續生物製程、高通量分析以及改進的上游工程正在重新定義生產經濟性和營運靈活性。同時，生物製藥模式也日益多元化，抗體藥物複合體(ADC)、雙特異性抗體、mRNA 產品、病毒載體以及自體或異體細胞療法均需要客製化的生產環境和複雜的防護策略。監管要求也在發生變化，更加重視可比性、無菌保證、製程驗證以及全球供應鏈網路中可追溯的數位化記錄。為了降低地緣政治動盪、物流限制和原料短缺帶來的風險，申辦方越來越重視雙重來源、區域分散式生產以及經認證的備用生產能力。從以批次為中心的生產模式轉向利用數位技術的數據驅動型生產模式轉變，正在加深人們對生產過程的理解；同時，永續性的壓力迫使製造商最佳化用水、能源消耗、耗材管理和減少廢棄物。這些變化正在將生物製劑契約製造從單純的交易型生產服務提升為支持治療創新領域的核心要素。

人工智慧對生物製藥生產的累積影響

人工智慧 (AI) 透過增強製程開發、品管、預測性維護、供應鏈規劃和法規遵從性，對生物製品契約製造的整體產生著累積的影響。在上游工程開發中，AI 驅動的建模能夠評估細胞培養參數、培養基最佳化、營養傳輸策略和關鍵製程變量，從而支持快速確定穩健的生產條件。在下游製程中，機器學習可用於分析源自製程分析技術和批次記錄的複雜資料集，從而改善層析法最佳化、雜質檢測和產率一致性。 AI 驅動的異常檢測有助於及早發現生物反應器、環境監測、公用設施和儀器性能方面的偏差，從而降低批次失敗的風險並提高生產的連續性。在品管操作中，自然語言處理和先進的分析技術擴大用於文件審查、追蹤偏差趨勢、支援調查以及改進全球製造地的知識管理。然而，實施這些技術需要檢驗的演算法、可解釋的模型、安全的資料架構以及符合有關電腦系統和資料完整性的法規要求。生物製品契約製造中最有效的 AI 策略是將科學專業知識與管理良好的數位基礎設施相結合，確保自動化能夠增強而不是取代嚴格的品管。

生物製劑契約製造的關鍵區域見解

亞太地區正透過不斷擴大生物製藥基礎設施、培養技術人才、推行扶持性產業政策以及對生物相似藥和先進療法日益成長的需求，加強其在生物製劑契約製造領域的作用。中國、印度、日本、韓國、澳洲和東南亞國協正投資於生物製藥園區、臨床生產能力和監管體系的現代化建設，以吸引技術轉移並增強國內供應的韌性。歐洲憑藉其高標準的監管體系、先進的生物製程工程和豐富的生物相似藥專業知識，以及完善的品質體系、連貫的藥物安全監測系統和覆蓋歐盟內外製造地的跨境供應鍊網路，繼續享有盛譽。北美憑藉其成熟的法規環境、眾多臨床階段創新企業的聚集、強大的學術研究基礎以及在哺乳動物細胞培養、病毒載體、分析表徵和無菌灌裝包裝方面的成熟能力，仍然是複雜生物製藥開發和商業化生產的核心樞紐。在拉丁美洲，隨著公共醫療體系擴大覆蓋範圍，生物製劑和生物相似藥的重要性日益凸顯。巴西和墨西哥等國正在推動區域生產舉措，以支持疫苗安全、技術轉移和價格最佳化。非洲雖然仍處於起步階段，但正處於一個具有戰略意義的關鍵節點。契約製造的機會正在湧現，這與疫苗生產、區域衛生安全、人力資源開發以及旨在減少對進口生物製劑依賴的夥伴關係相關。在中東，尤其是在那些將生命科學視為應對更廣泛經濟轉型挑戰的一部分的國家，對藥物本地化、生物製劑分銷基礎設施和醫療保健多元化策略的投資正在不斷增加。

我們團隊對全球生物製劑生產網路的關鍵見解。

儘管北約成員國並非醫療保健貿易集團，但許多成員國正日益重視生物製劑契約製造供應鏈的韌性，因為它們優先考慮安全的醫療保健供應鏈、應對疫情的準備、生物製藥生產的連續性，並減少對脆弱的外部關鍵生物製藥和疫苗原料來源的依賴。七國集團（G7）透過先進的監管科學、智慧財產權框架、研究經費、高品質的檢驗標準以及在細胞療法、基因療法、疫苗和抗體療法等複雜療法方面的專業知識，持續影響全球生物製劑的生產。金磚國家（BRICS）由於其龐大的患者群體、公共部門對價格合理的生物製藥的需求、對生物類似藥政策的支持以及在生物程序和生物製藥開發方面不斷增強的技術能力，發揮著日益重要的作用。歐盟（EU）提供高度協調的監管和品質環境，支持跨境生物製劑生產、生物相似藥開發、藥物安全監測的協調以及成員國之間標準化的合規要求。東協正憑藉其區域醫療保健的擴張、投資激勵措施、監管趨同的努力以及旨在增強藥品自主性的舉措（尤其是在疫苗、生物類似藥和無菌生產領域），崛起為生物製劑契約製造的關鍵區域集團。海灣合作理事會（GCC）正透過其在醫療保健多元化、採購系統現代化和醫藥基礎設施投資方面的努力，推動生命科學領域的本土化，從而為該地區的生物製藥灌裝和包裝、低溫運輸物流和分銷創造機遇。

主要國家生物製品契約製造的趨勢

受監管改革、不斷擴充的創新研發管線以及對抗體、疫苗、生物相似藥和細胞療法的需求推動，中國正在迅速擴大其生物製劑契約製造。美國在該領域處於領先地位，這得益於其強大的臨床階段生物技術開發公司生態系統、先進的生物程序技術、嚴格的法律規範以及對高度複雜生物製藥和細胞基因療法生產的強勁需求。日本在高品質生物製藥的開發、先進的生產標準以及精準療法的需求方面仍然舉足輕重，而印度則在生物相似藥、疫苗、具成本效益的生物程序和高素質的科研人才方面表現突出，並日益重視全球監管合規。德國是歐洲領先的製造地，擁有工程技術專長、完善的藥品品質系統和生物製藥製程開發能力。英國在先進療法、臨床生產、監管科學和轉化研究方面也擁有強大的實力。澳洲憑藉其在臨床試驗、轉化研究和區域生物製造領域的優勢，為生物製藥生產提供支持；法國則透過其國家產業戰略和醫療創新舉措，推動生物製藥和疫苗生產。韓國擁有大規模哺乳動物細胞培養能力、政府主導的生物製藥策略以及強大的出口導向生產基礎設施，是重要的生物製劑製造地。義大利憑藉其在無菌生產、製藥工程和契約製造的經驗做出貢獻；加拿大則透過對國內生物製造的公共投資、疫苗供應鏈的開發以及產學研合作來支持該行業。俄羅斯致力於生物製劑和生物相似藥的國內生產，以減少對進口的依賴，供應鏈本地化仍然是其核心政策促進因素。巴西是拉丁美洲的主要市場，這得益於其公共衛生採購需求、促進生物相似藥取得的措施以及支持本地生物製藥生產能力的技術轉移計劃。同時，墨西哥因其藥品近岸外包、熟練的生產人員以及接近性北美供應鏈的優勢而備受關注，但與傳統藥品生產相比，其生物製藥領域的能力仍然有限。西班牙則透過投資臨床研究基礎設施、推廣生物相似藥、加強生產，來提升其在生物製藥領域的能力。

為生物製劑生產領域的領導者提供的實用建議

產業領導者應優先考慮靈活的生產網路，將區域韌性與上游工程、下游、分析和填充/表面處理工程的技術專長相結合。在評估合作夥伴時，申辦方不僅應評估生產能力，還應評估監管檢查歷史、品質文化、技術轉移記錄、污染控制策略、資料完整性系統以及特定療法的專業知識。契約製造製造商應投資於一次性平台、自動化、數位化批次記錄、流程分析技術和人工智慧驅動的分析，同時確保驗證、網路安全和監管透明度。申辦者和製造商都應加強原料合格、供應商冗餘、低溫運輸可視性和基於風險的庫存計劃，以最大限度地減少中斷。對於先進療法，領導者應建立以目標為導向的生產模式，以應對保存期限短、患者特定物流、身份鏈、監管鍊和快速出貨前檢測等問題。此外，各組織需要將永續性納入設施設計和流程最佳化中，尤其是在無塵室、一次性耗材和用水等能源密集領域。最後，建立長期夥伴關係，並輔以清晰的管治、通用的績效指標、健全的變更管理程序和早期監管協調，對於減少延誤和提高生物製品生產的可靠性至關重要。

關於檢驗生物製品生產的知識調查方法

本執行摘要基於系統的二手研究方法，利用經核實的公共領域和行業特定資源，包括監管指南、現行藥品生產品質管理規範 (GMP) 框架、公共衛生和藥品監管機構出版刊物、同行評審的生物製程文獻、臨床試驗和生物製品核准趨勢、貿易政策參考資料以及已記錄的行業調查方法模式。本檢驗著重於有關生產能力、技術應用、監管趨勢、區域產業策略和供應鏈韌性的定性資訊來源，而非市場規模估算、收入預測、市場佔有率計算或未來預測。透過對多個資訊來源的檢驗，整合了相關見解，以識別生物製藥外包、生物相似藥生產、先進治療藥物生產、人工智慧驅動的生物製程和區域生產能力發展的通用主題。特別強調了監管現代化、生物製造基礎設施投資、人力和技術能力發展、特定療法生產要求以及品質系統預期等事實指標。該調查方法避免了檢驗的說法，並專注於可追溯的、基於證據的趨勢，這些趨勢影響著贊助商、契約製造、政策制定者和醫療保健供應鏈中的相關人員對生物製劑契約製造的決策。

結論：生物製劑契約製造的策略性展望

生物製劑契約製造正從單純的外包選項演變為一種策略營運模式，以促進生物製藥的創新、可及性和韌性。這一領域的發展受到生物製藥日益複雜化、生物相似藥需求不斷成長、先進療法不斷發展、區域生產政策以及對品質、可追溯性和供應穩定性的日益成長的期望等因素的影響。人工智慧、自動化、一次性技術和數位化整合品管系統正在提升對製程的理解和營運應對力，但這些都必須在檢驗、符合監管要求且科學嚴謹的框架內實施。在區域、集團和國家層面，成熟的生產基地在先進能力方面繼續發揮主導作用，而新興的生產區域正在建立能力，以提高可負擔性、自給自足性和醫療安全。擁有深厚的技術實力、卓越的監管能力、穩健的供應鏈網路和協作夥伴關係模式的行業相關人員將更有能力支持下一代生物製藥的發展。隨著生物製藥在全球醫療保健中扮演越來越重要的角色，契約製造將繼續成為實現可靠生產、加快研發進程和擴大患者可及性的關鍵驅動力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：生物製劑契約製造市場：依分子類型分類

  • 細胞療法
  • 基因治療
  • 單株抗體
  • 重組蛋白
  • 疫苗

第8章：生物製品契約製造市場：依製程階段分類

  • 分析測試
  • 下游
  • 填充和精加工
  • 配方
  • 上游

第9章：生物製劑契約製造市場：依生產規模分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前階段

第10章：生物製劑契約製造市場：依治療領域分類

  • 自體免疫
  • 感染疾病
  • 腫瘤學
  • 罕見疾病

第11章：生物製品契約製造市場：依最終用戶分類

  • 生技公司
  • 合約服務供應商
  • 製藥公司
  • 研究機構

第12章：生物製品契約製造市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：生物製品契約製造市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章：生物製品契約製造市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc
  • AGC Inc.
  • Almac Group
  • Asahi Kasei Medical Co., Ltd.
  • Avid Bioservices
  • BioNTech
  • Boehringer Ingelheim
  • Bora Pharmaceuticals Co Ltd
  • Charles River Laboratories
  • Cytovance Biologics
  • Emergent BioSolutions
  • Eurofins Scientific
  • FUJIFILM Corporation
  • GenScript Biotech Corporation
  • Jubilant HollisterStier LLC
  • KBI Biopharma
  • Lonza Group Ltd
  • National Resilience Inc
  • Novo Holdings A/S
  • Pfizer Inc.
  • Piramal Pharma Solutions
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Siegfried Holding AG
  • Syngene International
  • Thermo Fisher Scientific Inc
  • Vetter Pharma-Fertigung GmbH & Co. KG.
  • WuXi Biologics
Product Code: MRR-8C74ADFBFD4E

The Biologics Contract Manufacturing Market is projected to grow by USD 45.86 billion at a CAGR of 8.35% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 26.15 billion
Estimated Year [2026] USD 28.26 billion
Forecast Year [2032] USD 45.86 billion
CAGR (%) 8.35%

Biologics Contract Manufacturing Executive Summary

Biologics contract manufacturing has become a strategic pillar for biopharmaceutical developers seeking scalable, compliant, and cost-efficient production of monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, biosimilars, and next-generation biologic modalities. Demand is being shaped by complex molecule pipelines, rising biologic approvals, expanding biosimilar adoption, and the need for specialized capabilities across mammalian cell culture, microbial fermentation, viral vector production, fill-finish, analytical testing, and regulatory documentation. Unlike conventional small-molecule manufacturing, biologics production requires rigorous control of living systems, cold-chain integrity, contamination prevention, process characterization, and quality-by-design frameworks. As a result, sponsors increasingly rely on contract development and manufacturing organizations to accelerate clinical and commercial readiness while maintaining compliance with current good manufacturing practice standards. The sector is also influenced by supply-chain resilience priorities, localization policies, technology transfer requirements, and growing scrutiny over data integrity, batch traceability, and biologics safety. For industry stakeholders, competitive advantage depends on flexible capacity, advanced bioprocessing expertise, robust quality systems, and the ability to support end-to-end lifecycle needs from cell line development and process optimization to commercial manufacturing and post-approval change management.

Transformative Shifts Reshaping Biologics Manufacturing Outsourcing

The biologics contract manufacturing landscape is undergoing structural transformation as developers shift from single-product outsourcing toward integrated, long-term manufacturing partnerships. Single-use bioreactors, modular cleanroom infrastructure, closed processing, continuous bioprocessing, high-throughput analytics, and intensified upstream production are redefining production economics and operational agility. At the same time, biologic modalities are becoming more diverse, with antibody-drug conjugates, bispecific antibodies, mRNA-based products, viral vectors, and autologous or allogeneic cell therapies requiring tailored manufacturing environments and advanced containment strategies. Regulatory expectations are also evolving, with authorities emphasizing comparability, sterility assurance, process validation, and traceable digital records across global supply networks. Sponsors are increasingly prioritizing dual sourcing, regionalized production, and qualified backup capacity to reduce exposure to geopolitical disruption, logistics constraints, and raw material shortages. The shift from batch-centric operations to digitally enabled, data-rich manufacturing is improving process understanding, while sustainability pressures are encouraging manufacturers to optimize water use, energy consumption, consumables management, and waste reduction. These changes are positioning biologics contract manufacturing as a core enabler of therapeutic innovation rather than a transactional production service.

Cumulative Impact of Artificial Intelligence on Biologics Production

Artificial intelligence is having a cumulative impact across biologics contract manufacturing by strengthening process development, quality control, predictive maintenance, supply-chain planning, and regulatory readiness. In upstream development, AI-assisted modeling helps evaluate cell culture parameters, media optimization, feeding strategies, and critical process variables, supporting faster identification of robust manufacturing conditions. In downstream operations, machine learning can improve chromatography optimization, impurity detection, and yield consistency by analyzing complex datasets from process analytical technologies and batch records. AI-enabled anomaly detection supports early identification of deviations in bioreactors, environmental monitoring, utilities, and equipment performance, reducing the risk of batch failure and improving manufacturing continuity. In quality operations, natural language processing and advanced analytics are increasingly used to review documentation, trend deviations, support investigations, and improve knowledge management across global manufacturing sites. However, adoption requires validated algorithms, explainable models, secure data architectures, and alignment with regulatory expectations for computerized systems and data integrity. The most effective AI strategies in biologics contract manufacturing combine scientific domain expertise with governed digital infrastructure, ensuring that automation enhances rather than replaces rigorous quality oversight.

Key Regional Insights Across Biologics Contract Manufacturing

Asia-Pacific is strengthening its role in biologics contract manufacturing through expanding biopharmaceutical infrastructure, skilled technical workforces, supportive industrial policies, and growing demand for biosimilars and advanced therapies. China, India, Japan, South Korea, Australia, and ASEAN economies are investing in biologics parks, clinical manufacturing capacity, and regulatory modernization to attract technology transfer and improve domestic supply resilience. Europe continues to be recognized for high regulatory standards, advanced bioprocess engineering, and strong biosimilar expertise, supported by well-developed quality systems, pharmacovigilance alignment, and cross-border supply networks across European Union and non-EU manufacturing centers. North America remains a central hub for complex biologics development and commercial manufacturing because of its mature regulatory environment, concentration of clinical-stage innovators, strong academic research base, and established capabilities in mammalian cell culture, viral vectors, analytical characterization, and aseptic fill-finish. Latin America is gaining relevance as public health systems expand access to biologics and biosimilars, with regional manufacturing initiatives supporting vaccine security, technology transfer, and improved affordability in countries such as Brazil and Mexico. Africa is at an earlier but strategically important stage, with biologics contract manufacturing opportunities tied to vaccine production, regional health security, workforce development, and partnerships designed to reduce dependence on imported biologic medicines. The Middle East is increasing investment in pharmaceutical localization, biologics distribution infrastructure, and healthcare diversification strategies, particularly in countries pursuing life sciences as part of broader economic transformation agendas.

Key Group Insights in Global Biologics Manufacturing Networks

NATO member countries, while not a healthcare trade bloc, are increasingly relevant to biologics contract manufacturing supply-chain resilience because many members are prioritizing secure medical supply networks, pandemic preparedness, biomanufacturing continuity, and reduced dependence on vulnerable external sources for critical biologics and vaccine inputs. The G7 continues to influence global biologics manufacturing through advanced regulatory science, intellectual property frameworks, research funding, high-quality inspection standards, and specialized capabilities for complex modalities such as cell therapies, gene therapies, vaccines, and antibody-based therapeutics. BRICS countries play an increasingly important role because of their large patient populations, public-sector demand for affordable biologics, biosimilar policy support, and expanding technical capacity for bioprocessing and biologics development. The European Union provides a highly harmonized regulatory and quality environment that supports cross-border biologics manufacturing, biosimilar development, pharmacovigilance alignment, and standardized compliance expectations across member states. ASEAN is emerging as a relevant grouping for biologics contract manufacturing due to regional healthcare expansion, investment incentives, regulatory convergence efforts, and initiatives to strengthen pharmaceutical self-sufficiency, particularly in vaccines, biosimilars, and sterile manufacturing. The GCC is advancing life sciences localization through healthcare diversification initiatives, procurement modernization, and investment in pharmaceutical infrastructure, creating opportunities for fill-finish, cold-chain logistics, and regional biologics distribution.

Key Country Insights in Biologics Contract Manufacturing

China has rapidly expanded biologics contract manufacturing capabilities, driven by regulatory reforms, a growing innovation pipeline, and demand for antibodies, vaccines, biosimilars, and cell therapies. The United States leads activity through a deep ecosystem of clinical-stage biotechnology developers, advanced bioprocessing expertise, stringent regulatory oversight, and strong demand for high-complexity biologics and cell and gene therapy manufacturing. Japan remains important for high-quality biologics development, advanced manufacturing standards, and demand for precision therapies, while India is prominent in biosimilars, vaccines, cost-efficient bioprocessing, and skilled scientific talent with increasing focus on global regulatory compliance. Germany is a major European biomanufacturing center supported by engineering expertise, established pharmaceutical quality systems, and biologics process development strength, and the United Kingdom maintains strong capabilities in advanced therapies, clinical manufacturing, regulatory science, and translational research. Australia supports biologics manufacturing through clinical trial strengths, translational research, and regional biomanufacturing investment, while France is advancing biologics and vaccine manufacturing through national industrial strategies and healthcare innovation initiatives. South Korea has become a significant biologics manufacturing hub through large-scale mammalian cell culture capabilities, government-backed biopharmaceutical strategies, and strong export-oriented production infrastructure. Italy contributes through sterile manufacturing, pharmaceutical engineering, and contract production experience, and Canada supports the sector through public investment in domestic biomanufacturing, vaccine readiness, and academic-industry collaboration. Russia has emphasized domestic biologics and biosimilar production to reduce import reliance, with supply-chain localization remaining a central policy driver. Brazil is a key Latin American market due to public health procurement needs, biosimilar access initiatives, and technology transfer programs supporting local biologics capacity, while Mexico is gaining attention for pharmaceutical nearshoring, skilled manufacturing labor, and proximity to North American supply chains, although biologics capabilities remain more selective than conventional pharmaceutical production. Spain is strengthening biologics capabilities through clinical research infrastructure, biosimilar adoption, and manufacturing investments.

Actionable Recommendations for Biologics Manufacturing Leaders

Industry leaders should prioritize flexible manufacturing networks that combine regional resilience with technical specialization across upstream, downstream, analytical, and fill-finish operations. Sponsors should evaluate partners not only on capacity, but also on regulatory inspection history, quality culture, technology transfer performance, contamination control strategy, data integrity systems, and modality-specific expertise. Contract manufacturers should invest in single-use platforms, automation, digital batch records, process analytical technologies, and AI-enabled analytics while ensuring validation, cybersecurity, and regulatory transparency. Both sponsors and manufacturers should strengthen raw material qualification, supplier redundancy, cold-chain visibility, and risk-based inventory planning to reduce disruptions. For advanced therapies, leaders should establish fit-for-purpose manufacturing models that address short shelf life, patient-specific logistics, chain of identity, chain of custody, and rapid release testing. Organizations should also embed sustainability into facility design and process optimization, particularly around energy-intensive cleanrooms, disposable consumables, and water use. Finally, long-term partnerships with clear governance, shared performance metrics, robust change-control procedures, and early regulatory alignment will be essential for reducing delays and improving biologics manufacturing reliability.

Research Methodology for Verified Biologics Manufacturing Insights

This executive summary is based on a structured secondary research methodology using verified public-domain and industry-relevant sources, including regulatory agency guidance, current good manufacturing practice frameworks, public health and medicines authority publications, peer-reviewed bioprocessing literature, clinical trial and biologics approval trends, trade policy references, and documented industry investment patterns. The analysis emphasizes qualitative evidence on manufacturing capabilities, technology adoption, regulatory developments, regional industrial strategies, and supply-chain resilience rather than market sizing, revenue estimation, share calculation, or forecasting. Insights were synthesized through cross-source validation to identify consistent themes across biologics outsourcing, biosimilar production, advanced therapy manufacturing, AI-enabled bioprocessing, and regional capacity development. Particular attention was given to factual indicators such as regulatory modernization, biomanufacturing infrastructure investment, workforce and technical capability development, modality-specific production requirements, and quality-system expectations. The methodology avoids unverified claims and focuses on traceable, evidence-backed dynamics shaping biologics contract manufacturing decisions for sponsors, contract manufacturers, policymakers, and healthcare supply-chain stakeholders.

Conclusion: Strategic Outlook for Biologics Contract Manufacturing

Biologics contract manufacturing is evolving from an outsourcing option into a strategic operating model for biopharmaceutical innovation, access, and resilience. The sector is shaped by increasing biologic complexity, expanding biosimilar demand, advanced therapy growth, regional manufacturing policies, and heightened expectations for quality, traceability, and supply security. Artificial intelligence, automation, single-use technologies, and digitally connected quality systems are improving process understanding and operational responsiveness, but they must be implemented within validated, compliant, and scientifically robust frameworks. Regional, group, and country-level dynamics show that mature hubs continue to lead in advanced capabilities, while emerging manufacturing regions are building capacity to improve affordability, self-sufficiency, and healthcare security. Industry participants that combine technical depth, regulatory excellence, resilient supply networks, and collaborative partnership models will be best positioned to support the next generation of biologic medicines. As biologics become central to global healthcare, contract manufacturing will remain a critical enabler of reliable production, faster development pathways, and broader patient access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biologics Contract Manufacturing Market, by Molecule Type

  • 7.1. Introduction
  • 7.2. Cell Therapy
  • 7.3. Gene Therapy
  • 7.4. Monoclonal Antibody
  • 7.5. Recombinant Protein
  • 7.6. Vaccine

8. Biologics Contract Manufacturing Market, by Process Step

  • 8.1. Introduction
  • 8.2. Analytical Testing
  • 8.3. Downstream
  • 8.4. Fill Finish
  • 8.5. Formulation
  • 8.6. Upstream

9. Biologics Contract Manufacturing Market, by Production Scale

  • 9.1. Introduction
  • 9.2. Phase I
  • 9.3. Phase II
  • 9.4. Phase III
  • 9.5. Preclinical

10. Biologics Contract Manufacturing Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Autoimmune
  • 10.3. Infectious Disease
  • 10.4. Oncology
  • 10.5. Rare Disease

11. Biologics Contract Manufacturing Market, by End User

  • 11.1. Introduction
  • 11.2. Biotechnology Company
  • 11.3. Contract Service Provider
  • 11.4. Pharmaceutical Company
  • 11.5. Research Institute

12. Biologics Contract Manufacturing Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Biologics Contract Manufacturing Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Biologics Contract Manufacturing Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc
  • 16.2. AGC Inc.
  • 16.3. Almac Group
  • 16.4. Asahi Kasei Medical Co., Ltd.
  • 16.5. Avid Bioservices
  • 16.6. BioNTech
  • 16.7. Boehringer Ingelheim
  • 16.8. Bora Pharmaceuticals Co Ltd
  • 16.9. Charles River Laboratories
  • 16.10. Cytovance Biologics
  • 16.11. Emergent BioSolutions
  • 16.12. Eurofins Scientific
  • 16.13. FUJIFILM Corporation
  • 16.14. GenScript Biotech Corporation
  • 16.15. Jubilant HollisterStier LLC
  • 16.16. KBI Biopharma
  • 16.17. Lonza Group Ltd
  • 16.18. National Resilience Inc
  • 16.19. Novo Holdings A/S
  • 16.20. Pfizer Inc.
  • 16.21. Piramal Pharma Solutions
  • 16.22. Recipharm AB
  • 16.23. Rentschler Biopharma SE
  • 16.24. Samsung Biologics
  • 16.25. Siegfried Holding AG
  • 16.26. Syngene International
  • 16.27. Thermo Fisher Scientific Inc
  • 16.28. Vetter Pharma-Fertigung GmbH & Co. KG.
  • 16.29. WuXi Biologics

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANALYTICAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANALYTICAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANALYTICAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DOWNSTREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DOWNSTREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DOWNSTREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FILL FINISH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FILL FINISH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FILL FINISH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FORMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FORMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UPSTREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UPSTREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UPSTREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RARE DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RARE DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RARE DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOTECHNOLOGY COMPANY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOTECHNOLOGY COMPANY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOTECHNOLOGY COMPANY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONTRACT SERVICE PROVIDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CONTRACT SERVICE PROVIDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONTRACT SERVICE PROVIDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL COMPANY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL COMPANY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL COMPANY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESEARCH INSTITUTE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RESEARCH INSTITUTE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESEARCH INSTITUTE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 115. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 116. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 117. NATO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 121. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 123. G7 BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 164. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 165. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 170. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 171. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 172. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 176. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 177. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 178. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 188. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 189. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 200. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 201. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 218. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 219. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2032 (USD MILLION)
  • TABLE 236. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 237. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 240. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025